1 |
Khalil V, Wang W, Charlson L, et al(2019). Evaluation of prescribing patterns of nonsteroidal anti-inflammatory agents in a tertiary setting. Int J Evid Based Healthc, 17(3), 164-172. https://doi.org/10.1097/XEB.000000000000173.
DOI
|
2 |
Kim HC, Lee MC, Moon YW, et al(2011). The pattern of use of oral NSAIDs with or without co-prescription of gastroprotective agent for arthritic knee by Korean practitioners. Knee Surg Relat Res, 23(4), 203-207.
DOI
|
3 |
Kim YI, Kim SM(2019). National health insurance statistical yearbook. Wonju, National Health Insurance Service and Health Insurance Review & Assessment Service.
|
4 |
Korea Centers for Disease Control and Prevention(2017). The seventh Korea National Health and Nutrition Examination Survey (KNHANES VII-2). Korea centers for disease control and prevention.
|
5 |
Lanza FL, Chan FKL, Quigley EMM(2009). Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol, 104(3), 728-738. https://doi.org/10.1038/jg.2009.115.
DOI
|
6 |
Larkai EN, Smith JL, Lidsky MD, et al(1987). Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol, 82(11), 1153-1158.
|
7 |
Micklewright R, Lane S, Linley W, et al(2003). Review article: NSAIDs, gastroprotection and cyclo-oxygenaseI-selective inhibitors. Aliment Pharmacol Ther, 17(3), 321-332. https://doi.org/10.1046/j.1365-2036.2003.01454.x.
DOI
|
8 |
Richmond J, Hunter D, Irrgang J, et al(2009). Treatment of Osteoarthritis of the Knee (Nonarthroplasty). J Am Acad Orthop Surg, 17(9), 591-600. https://doi.org/10.5435/00124635-200909000-00006.
DOI
|
9 |
Rostom A, Dube C, Wells GA, et al(2002). Prevention of NSAID-induced gastroduodenal ulcers. Cochrane database Syst Rev. Printed Online. https://doi.org/0.1002/4651858.CD002296.
|
10 |
Silverstein FE, Faich G, Goldstein JL, et al(1987). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA, 284(10), 1247-1255. https://doi.org/10.1001/jama.284.10.1247.
DOI
|
11 |
Tenenbaum J(1999). The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol, 13(2), 119-122. https://doi.org/10.1155/1999/361651.
DOI
|
12 |
Tsumura H, Tamura I, Tanaka H, et al(2007). Prescription of nonsteroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopedists in Japan. Intern Med, 46(13), 927-931. https://doi.org/10.2169/internalmedicine.46.0003.
DOI
|
13 |
Gabriel SE, Jaakkimainen L, Bombardier C(1991). Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med, 115(1), 787-796. https://doi.org/0.7326/003-4819-115-10-787.
DOI
|
14 |
Valkhoff VE, Van Soest EM, Masclee GMC, et al(2012). Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal -a 617,400-patient study. Aliment Pharmacol Ther, 36(8), 790-799. https://doi.org/10.1111/apt.12028.
DOI
|
15 |
Wolfe MM, Lichtenstein DR, Singh G(1999). Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med, 340(24), 1888-1899. https://doi.org/10.1056/NEJM199906173402407.
DOI
|
16 |
Zhang W, Moskowitz RW, Nuki G, et al(2008). OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil, 16(2), 137-162. https://doi.org/10.1016/j.joca.2007.12.013.
DOI
|
17 |
Bombardier C, Laine L, Reicin A, et al(2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med, 343(21), 1520-1528. https://doi.org/10.1056/NEJM200011233432103.
DOI
|
18 |
Carvajal A, Martin Arias LH, Vega E, et al(2004). Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study. Eur J Clin Pharmacol, 60(6), 439-444. https://doi.org/10.1007/s00228-004-0782-8.
DOI
|
19 |
Chan FKL, Lanas A, Scheiman J, et al(2010). Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet, 376(9736), 173-179. https://doi.org/10.1016/S0140-6736(10)60673-3.
DOI
|
20 |
Cooper C, Chapurlat R, Al-Daghri N, et al(2019). Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: What does the literature say?. Drugs Aging, 36(Suppl 1), 15-24. https://doi.org/10.1007/40266-019-00660-1.
DOI
|
21 |
Glasziou P, Haynes B(2005). The paths from research to improved health outcomes. BMJ Evidence-Based Medicine, 10(1), 4-7. https://doi.org/10.1136/ebm.10.1.4-a.
DOI
|
22 |
Griffin MR, Piper JM, Daugherty JR, et al(1991). Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med, 114(4), 257-263. https://doi.org/10.7326/003-4819-114-4-257.
DOI
|
23 |
Griffin MR, Ray WA, Schaffner W(1988). Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med, 109(5), 359-363. https://doi.org/10.7326/0003-4819-109-5-359.
DOI
|
24 |
Han MH, Nam JH, Noh ES, et al(2019). Gastrointestinal risk of non-steroidal anti-inflammatory drugs and gastroprotective agents used in the treatment of osteoarthritis in elderly patients: A nationwide retrospective cohort study. Int J Clin Pharmacol Ther, 57(11), 531-541. https://doi.org/10.5414/CP203377.
DOI
|